Correlation between lipid profile and molecular typing of invasive breast cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LÜ Hongying , NIE Xianli , WANG Song ,  QUAN Yi

Department of Breast Surgery, A ffiliated Hospital of Southwest Medical University, Luzhou, Sichuang 646000, P. R. China;

Corresponding author：

QUAN Yi, Email: 20783833@qq.com

Keywords：

breast cancer; blood lipids; apolipoprotein; molecular typing

DOI：

10.7507/1007-9424.202006045

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the correlation between lipid profile and molecular typing of invasive breast cancer.Methods Three hundreds and seventy-five patients with primary invasive breast cancer diagnosed from Breast Surgery, Affiliated Hospital of Southwest Medical University from January 2018 to June 2019. The total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), Low-density lipoprotein cholesterol (LDL-C), apolipoprotein A (ApoA), and apolipoprotein B (ApoB) concentrations were detected. Molecular classification based on the results of postoperative immunohistochemistry of breast cancer patients, compared the measured values of each subtype.Results There were no significant difference in serum TG, HDL-C and ApoA among the four subtypes (P>0.05). Differences serum levels of TC, LDL-C, and ApoB among breast cancer patients of various subtypes were statistically significant (P<0.05). Serum TC concentration in the HER2 overexpression type [(5.08±1.00) mmol/L] and the triple negative type [(5.12±0.91) mmol/L] were significantly higher than the Luminal A type [(4.68±1.01) mmol/L] and the Luminal B type [(4.79± 0.93) mmol/L], P<0.05. Serum LDL-C concentration in the triple negative type [(3.14±0.88) mmol/L] was significantly higher than the LuminalA type [(2.77±0.84) mmol/L] and the LuminalB type [(2.87±0.81) mmol/L], P<0.05. Serum ApoB concentration in the Luminal B type [(0.94±0.23) g/L] was significantly lower than the triple negative type [(1.03±0.23) g/L].Conclusion There are differences in serum TC, LDL-C and apoB concentrations among different subtypes of breast cancer, but TG, HDL-C and ApoA are not related to molecular typing of breast cancer.

Citation： LÜ Hongying, NIE Xianli, WANG Song, QUAN Yi. Correlation between lipid profile and molecular typing of invasive breast cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(3): 336-340. doi: 10.7507/1007-9424.202006045 Copy

1.	DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin, 2017, 67(6): 439-448.
2.	Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Ltt, 2017, 401: 63-71.
3.	Coller HA. Is cancer a metabolic disease? Am J Pathol, 2014, 184(1): 4-17.
4.	Wang D, Yin L, Wei J, et al. ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis. Tumor Biol, 2017, 39(4): 1-10.
5.	Baek AE, Nelson ER. The contribution of cholesterol and its metabolites to the pathophysiology of breast cancer. Horm Cancer, 2016, 7(4): 219-228.
6.	Fichtali K, Bititi A, Elghanmi A, et al. Serum lipidomic profiling in breast cancer to identify screening, diagnostic, and prognostic biomarkers. Biores Open Access, 2020, 9(1): 1-6.
7.	Chen X, Chen H, Dai M, et al. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget, 2016, 7(24): 36622-36631.
8.	Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 2013, 24(9): 2206-2223.
9.	Perrotti F, Rosa C, Cicalini I, et al. Advances in lipidomics for cancer biomarkers discovery. Int J Mol sci, 2016, 17(12): 1992.
10.	Eiriksson FF, Nøhr MK, Costa M, et al. Lipidomic study of cell lines reveals differences between breast cancer subtypes. PLoS One, 2020, 15(4): 1-22.
11.	Cappelletti V, Iorio E, Miodini P, et al. Metabolic footprints and molecular subtypes in breast cancer. Dis Markers, 2017, 2017: 7687851.
12.	Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget, 2017, 8(17): 29487-29500.
13.	Currie E, Schulze A, Zechner R, et al. Cellular fatty acid metabolism and cancer. Cell Metab, 2013, 18(2): 153-161.
14.	Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Bio, 2014, 24(8): 472-478.
15.	Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science, 2010, 327(5961): 46-50.
16.	Ehmsen S, Pedersen MH, Wang G, et al. Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome. Cell Rep, 2019, 27(13): 3927-3938. e6.
17.	Kitahara CM, De González AB, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Cli Oncol, 2011, 29(12): 1592.
18.	His M, Zelek L, Deschasaux M, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol, 2014, 29(2): 119-132.
19.	Hidaka BH, Kimler BF, Fabian CJ, et al. An empirically derived dietary pattern associated with breast cancer risk is validated in a nested case-control cohort from a randomized primary prevention trial. Cli Nutr ESPEN, 2017, 17: 8-17.
20.	Fagherazzi G, Fabre A, Boutron-Ruault MC, et al. Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev, 2010, 19(2): 120-125.
21.	Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J NatI Cancer Inst, 2011, 103(19): 1461-1468.
22.	Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. Breast, 2011, 20(6): 485-490.
23.	Asaga S, Kinoshita T, Hojo T, et al. Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy. Clin Breast Cancer, 2013, 13(1): 40-46.
24.	Wan F, Qin X, Zhang G, et al. Oxidized low-density lipoprotein is associated with advanced-stage prostate cancer. Tumor Biol, 2015, 36(5): 3573-3582.
25.	Ye J, Xia X, Dong W, et al. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines. Int J Nanomedicine, 2016, 11: 4125-4140.
26.	Antalis CJ, Uchida A, Buhman KK, et al. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis, 2011, 28(8): 733-741.
27.	Rodrigues Dos Santos C, Fonseca I, Dias S, et al. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer, 2014, 14: 132.

1. DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin, 2017, 67(6): 439-448.
2. Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Ltt, 2017, 401: 63-71.
3. Coller HA. Is cancer a metabolic disease? Am J Pathol, 2014, 184(1): 4-17.
4. Wang D, Yin L, Wei J, et al. ATP citrate lyase is increased in human breast cancer, depletion of which promotes apoptosis. Tumor Biol, 2017, 39(4): 1-10.
5. Baek AE, Nelson ER. The contribution of cholesterol and its metabolites to the pathophysiology of breast cancer. Horm Cancer, 2016, 7(4): 219-228.
6. Fichtali K, Bititi A, Elghanmi A, et al. Serum lipidomic profiling in breast cancer to identify screening, diagnostic, and prognostic biomarkers. Biores Open Access, 2020, 9(1): 1-6.
7. Chen X, Chen H, Dai M, et al. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget, 2016, 7(24): 36622-36631.
8. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol, 2013, 24(9): 2206-2223.
9. Perrotti F, Rosa C, Cicalini I, et al. Advances in lipidomics for cancer biomarkers discovery. Int J Mol sci, 2016, 17(12): 1992.
10. Eiriksson FF, Nøhr MK, Costa M, et al. Lipidomic study of cell lines reveals differences between breast cancer subtypes. PLoS One, 2020, 15(4): 1-22.
11. Cappelletti V, Iorio E, Miodini P, et al. Metabolic footprints and molecular subtypes in breast cancer. Dis Markers, 2017, 2017: 7687851.
12. Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget, 2017, 8(17): 29487-29500.
13. Currie E, Schulze A, Zechner R, et al. Cellular fatty acid metabolism and cancer. Cell Metab, 2013, 18(2): 153-161.
14. Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Bio, 2014, 24(8): 472-478.
15. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science, 2010, 327(5961): 46-50.
16. Ehmsen S, Pedersen MH, Wang G, et al. Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome. Cell Rep, 2019, 27(13): 3927-3938. e6.
17. Kitahara CM, De González AB, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Cli Oncol, 2011, 29(12): 1592.
18. His M, Zelek L, Deschasaux M, et al. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol, 2014, 29(2): 119-132.
19. Hidaka BH, Kimler BF, Fabian CJ, et al. An empirically derived dietary pattern associated with breast cancer risk is validated in a nested case-control cohort from a randomized primary prevention trial. Cli Nutr ESPEN, 2017, 17: 8-17.
20. Fagherazzi G, Fabre A, Boutron-Ruault MC, et al. Serum cholesterol level, use of a cholesterol-lowering drug, and breast cancer: results from the prospective E3N cohort. Eur J Cancer Prev, 2010, 19(2): 120-125.
21. Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J NatI Cancer Inst, 2011, 103(19): 1461-1468.
22. Valachis A, Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. Breast, 2011, 20(6): 485-490.
23. Asaga S, Kinoshita T, Hojo T, et al. Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy. Clin Breast Cancer, 2013, 13(1): 40-46.
24. Wan F, Qin X, Zhang G, et al. Oxidized low-density lipoprotein is associated with advanced-stage prostate cancer. Tumor Biol, 2015, 36(5): 3573-3582.
25. Ye J, Xia X, Dong W, et al. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines. Int J Nanomedicine, 2016, 11: 4125-4140.
26. Antalis CJ, Uchida A, Buhman KK, et al. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin Exp Metastasis, 2011, 28(8): 733-741.
27. Rodrigues Dos Santos C, Fonseca I, Dias S, et al. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer, 2014, 14: 132.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Correlation between lipid profile and molecular typing of invasive breast cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content